Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. (13th July 2018)

• Record Type: Journal Article
• Authors: Hanna, G J; Supplee, J G; Kuang, Y; Mahmood, U; Lau, C J; Haddad, R I; Jänne, P A; Paweletz, C P
• Is Part Of: Annals of oncology. Volume 29:Number 9(2018)
• Page Start: 1980
• Page End: 1986
• Publication Date: 2018-07-13
• Subjects: head and neck cancer -- HPV -- cell-free DNA -- ddPCR; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdy251
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Measuring cell-free (cf)DNA in blood and tissues holds significant potential as a minimally invasive method for disease monitoring in cancer. Cancers arising in the oropharynx and causally linked to human papillomavirus (HPV) represent an ideal model in which to interrogate these methods. Patients and methods: We designed an ultrasensitive and quantitative droplet digital (dd)PCR assay to detect the five dominant high-risk HPV subtypes linked to oropharyngeal cancer (OPC). We enrolled a pilot observational cohort of 22 patients with advanced HPV+ OPC to evaluate the clinical utility of our assay and explore its predictive and prognostic potential. Results: Total tumor burden (TTB) strongly correlated with HPV cfDNA levels ( R = 0.91, P = 2.3×10 −6 ) at this cohort size, and in most cases more distant anatomic disease locations predicted increasing HPV cfDNA levels. All participants demonstrated a corresponding change in their HPV cfDNA levels at a median of 16 days (range 12–38) before restaging scans confirming treatment response or progression. Patients with locoregional disease in the head and neck or pulmonary-only metastases had worse outcomes ( P = 0.01). Both TTB and median plasma HPV cfDNA levels negatively correlated with survival ( R =−0.65, P = 0.01; R =−0.48, P = 0.05, respectively). Conclusion(s): Plasma HPV cfDNA monitoring recapitulates fluctuations in disease status. While blood-based HPV DNA monitoring does not currently have a role in managing HPV+ OPC, these data speak to their broad clinical potential in an era of precision medicine.